Ticker Details
Amicus Therapeutics, Inc. Amicus Therapeutics Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of next-generation medicines.
IPO Date:	May 31, 2007
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$4.55B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.23 | 2.63%
Avg Daily Range (30 D):	$0.01 | 0.04%
Avg Daily Range (90 D):	$0.01 | 0.10%

Institutional Daily Volume
Avg Daily Volume:	1.66M
Avg Daily Volume (30 D):	.93M
Avg Daily Volume (90 D):	3.09M

Trade Size
Avg Trade Size (Sh.):	156
Avg Trade Size (Sh.) (30 D):	252
Avg Trade Size (Sh.) (90 D):	301

Institutional Trades
Total Institutional Trades:	8,565
Avg Institutional Trade:	$2.99M
Avg Institutional Trade (30 D):	$3.09M
Avg Institutional Trade (90 D):	$3.79M
Avg Institutional Trade Volume:	.26M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$3.83M
Avg Closing Trade (30 D):	$4.39M
Avg Closing Trade (90 D):	$6.8M
Avg Closing Volume:	343.42K

News

Apr 25, 2026 @ 3:13 PM CIBRA Capital Makes a Big Merger Arbitrage Bet On ... Source: Cory Renauer

Feb 19, 2026 @ 11:30 PM Halper Sadeh LLC is Investigating Whether RAPT, CT... Source: Halper Sadeh Llc

Feb 19, 2026 @ 9:48 PM $HAREHOLDER ALERT: The M&A Class Action Firm Encou... Source: Monteverde & Associates Pc

Jan 7, 2026 @ 7:27 PM Halper Sadeh LLC Encourages EKSO, FOLD, CWAN, JHG ... Source: Halper Sadeh Llc

Jan 6, 2026 @ 7:58 PM Halper Sadeh LLC Encourages EKSO, FOLD, CWAN, JHG ... Source: Halper Sadeh Llc

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.09	$	$-.09
Diluted EPS	$-.09	$	$-.09
Revenue	$634.21M	$185.21M	$634.21M
Gross Profit	$561.28M	$158.67M	$561.28M
Net Income / Loss	$-27.11M	$1.69M	$-27.11M
Operating Income / Loss	$32.79M	$15.95M	$32.79M
Cost of Revenue	$72.93M	$26.55M	$72.93M
Net Cash Flow	$.6M	$23.46M	$.6M
PE Ratio